Experts provide their recommendations for navigating a large and continuously growing treatment landscape, selecting between regimens, and monitoring patients with transplant-ineligible multiple myeloma.
EP. 1: Goals of Therapy for Transplant-Ineligible MM
Kicking off a discussion regarding treatment approaches for transplant-ineligible multiple myeloma, a panel of hematologist-oncologists highlights goals of therapy for newly diagnosed patients.
EP. 2: Strategies to Monitor Multiple Myeloma
Different markers and tests that are used to monitor disease status and treatment response in patients with multiple myeloma.
EP. 3: Frequency of Measuring Treatment Response in MM
Recommendations for measuring treatment response in patients with multiple myeloma utilizing tests such as MRD assessments.
EP. 4: MRD Testing in Multiple Myeloma
Current techniques used to assess MRD status in patients with multiple myeloma, and advice to hematologist-oncologists who are considering flow cytometry or molecular testing.
EP. 5: Managing Adequate/Inadequate Treatment Response in MM
Recommended next steps regarding treatment for patients with transplant-ineligible multiple myeloma based on prior responses to therapy.
EP. 6: Managing A Case of Newly-Diagnosed Transplant-Ineligible MM
A panel of hematologist-oncologists comment on how they would treat a 74-year-old patient with newly diagnosed transplant-ineligible multiple myeloma.
EP. 7: Triplet Vs Doublet Therapy for Transplant-Ineligible MM
Scenarios for which a doublet regimen may be recommended over a triplet therapy for the management of newly diagnosed transplant-ineligible multiple myeloma.
EP. 8: Maintenance Therapy for Transplant-Ineligible MM
Take-home points from the MAIA trial of daratumumab plus lenalidomide and dexamethasone as therapy for patients with newly diagnosed transplant-ineligible multiple myeloma, and recommendations regarding maintenance therapy following the use of a triplet regimen.
EP. 9: Transplant-Ineligible MM: Treating to Progression
The rationale behind treating patients with newly diagnosed transplant-ineligible multiple myeloma (MM) until disease progression rather than stopping therapy at a designated point in time.
EP. 10: Transplant-Ineligible MM: Reinitiating Therapy
Triggers that may lead a hematologist/oncologist to consider reinstituting therapy for a patient with transplant-ineligible multiple myeloma (MM) who received prior therapy but was not treated to progression.
EP. 11: Counseling Patients With MM About Treatment Duration
Recommendations when talking with patients with transplant-ineligible multiple myeloma (MM) who request to stop receiving treatment.
EP. 12: Transplant-Ineligible MM: Navigating Treatment Challenges
A panel of hematologists/oncologists conclude a discussion about transplant-ineligible multiple myeloma (MM) by reacting to current treatment gaps that need to be addressed.
EP. 13: Management of Transplant-Ineligible Multiple Myeloma
2 Clarke Drive Cranbury, NJ 08512